Calistoga Pharmaceutical drugs, Corporation, the best choice in the introduction of isoform-selective PI3 kinase inhibitors for treating cancer and inflammatory illnesses, today introduced the presentation of information showing the Company’s dental, p110δ(delta) selective PI3 kinase inhibitor CAL-101 has broad preclinical anti-tumor activity against a variety of hematologic malignancies. Data were presented within an dental presentatiSeparate poster presentations of studies carried out in Dr. John Byrd’s laboratory in the Comprehensive Cancer Center in the Ohio Condition College and Dr. Kenneth Anderson’s laboratory in the Dana-Farber Cancer Institute at Harvard School Of Medicine shown preclinical effectiveness for CAL-101 in types of chronic lymphocytic leukemia and multiple myeloma, correspondingly.on and 2 poster presentations in the American Society of Hematology’s 50th Annual Meeting and Exposition in Bay Area, CA.
Results presented by Dr. John Lannutti, Senior Researcher, Calistoga Pharmaceutical drugs, shown that p110δ, whose expression under normal conditions is basically limited to leukocytes, was highly expressed in >90% of hematologic cancer cell lines, including diffuse large B cell lymphoma, layer cell lymphoma and acute lymphocytic leukemia (ALL) as well as in primary ALL patient samples. When these cell lines and primary patient cells were given CAL-101, proof of path inhibition and cytotoxicity was observed, supporting the role of p110δ during these malignancies.
“These bits of information demonstrate the potential for CAL-101 to selectively concentrate on the PI3K inhibitor path in hematologic malignancies to induce cancer cell dying,” stated Dr. Neill Giese, PhD, Chief Scientific Officer of Calistoga Pharmaceutical drugs. “We’ve shown preclinical evidence of concept with this particular selective approach and that we accept is as true may circumvent the possibility toxicities that will likely derive from pan PI3K inhibition.”
“Our ongoing Phase 1 medical trial provides our first chance to validate this novel approach in patients with hematological malignancies,” noted Dr. Carol Gallagher, Pharm.D., Ceo of Calistoga Pharmaceutical drugs. “CAL-101 may be the first inside a portfolio of selective PI3 kinase inhibitor agents that people intend to evaluate scientifically for treating cancer and inflammatory illnesses.”
- Selleckchem PIM Kinase Inhibitor SGI-1776 produces tumor regression in acute myologenous leukemia (AML) xenograft models
- Novel specific therapeutics: inhibitors of MDM2, ALK and PARP
- Treatment Of AML cells with PIM Kinase inhibitor Midostaurin and a mutation with FLT3
- Cells in RAD51D like Parp inhibitor were sensitive to treatment Ovarian Cancer drug
- ALK-Targeted Treatment for Lung Cancer